Cargando…
A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial
BACKGROUND: Neuroprotective agents have the potential to improve the outcomes of revascularisation therapies in acute ischemic stroke patients (AIS) and in those unable to receive revascularisation. Afamelanotide, a synthetic α-melanocyte stimulating hormone analogue, is a potential novel neuroprote...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373257/ https://www.ncbi.nlm.nih.gov/pubmed/37496004 http://dx.doi.org/10.1186/s12883-023-03338-9 |